1 / 17

Workshop 2 Supply reasons

Workshop 2 Supply reasons. Reasons for medicines shortages. Big Yellow Taxi. Don't it always seem to go That you don't know what you've got Till it's gone They paved paradise And put up a parking lot Joni Mitchell (1970). What are the causes of shortages . Regulatory (Tony Gill)

margie
Download Presentation

Workshop 2 Supply reasons

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Workshop 2 Supply reasons Reasons for medicines shortages

  2. Big Yellow Taxi • Don't it always seem to go That you don't know what you've got Till it's gone They paved paradise And put up a parking lot • Joni Mitchell (1970)

  3. What are the causes of shortages • Regulatory (Tony Gill) • API (Maura Kinahan) • Production (David Gaugh) • Distribution chain (Dawn Jennings) • Economics, Incentive Business ( Julie Tam)

  4. Regulatory • Needs to be consistency between the regulators • Predictability of the regulation (transition) • Inspection of manufacturers sometimes cause delays • Many times there is a degree of understanding....

  5. Regulatory - continue 5. Rigid regulatory frameworks are restrictive and burdensome in some cases • May not be applicable to other parts of the world 7. Variations of interpretation 8. Backlogs of inspections, licensing expires whilst waiting for inspection

  6. Regulatory - continue 9. Lack of transparency can cause issues 10. Needs to be transparent

  7. API Hugely complex. Key issues: • Reliance on China and India – risk perspective; and that they are both very different; how do you introduce standards • Lack of quality standards • Capacity of the API to handle global demands • Risk management- more inspections; turn around time; in terms of general business

  8. API - continue • Lack of incentives, downwards pressure on price always. Keep pushing the price down and there is risk of breaking • Sharing inspections with rest of the world- avoid duplicity

  9. Production • Regulatory actions need to be addressed more robustly, collaborating with reg affairs and companies • Need to be priority policies for expediting review of some products

  10. Production - continue 3. Production planning and specifically for injectables; need to know the plans and commit to the tender and ensure you can meet that need [tenders need to be tight] 4. Back up contingencies need to be in place. 5. Risk sharing – whether govt or some other company in another country. Are they willing to share the risk if the numbers tendered varied?

  11. Distribution • Community HCPs e.g. dentists no access to GPO and access to resources to keep managing a shortage and help with costs • Forecasting is based on seasonal trends • Wholesalers are dependent on manufacturers and are obligated to wait for industry for allocation • No framework for just allocation or best practice in relation to distribution

  12. Distribution (continue) • Stock piles in our region/ not in all countries • Distribution ; used to be no mediators – so many mediators make for a large level of opaque transparency • Sole suppliers – makes system vulnerable • Vulnerability for raw materials – seasonal • Emergence of new nations as suppliers and whether questionable GMP and more difficult to maintain supply

  13. Distribution - continue • Lean inventory instead of just in time • Lack of definition of necessary meds • Lack of ethical framework • Allocation differ in rules • Emergence and vulnerability of gray and counterfeit markets • Medicines open on the broad global market

  14. Distribution (continue) 16. Lack of oversight and an absence of indicators pointing to potential 17. Stockpiling and govt 18.Contingency plans not robust 19. Responsible communication of drug shortages 20. Lack of coordination of production capacity

  15. Economics, incentives business - continue • Profitability; if they have the incentive they will produce; • Need to incentivise manufacturers • Accountability: to whom? Shareholders? Patients? • Old vs new products profitability • Upgrade facilities • Consolidation of manufacturing

  16. Economics, incentives business - continue • Competition between countries • Purchasing/payer policies • Private vs public companies • Even within manufacturers some have long term and others short term decision making • Generic shortages exist; brand have 100% market

  17. Economics, incentives business - continue • Competition rules that do not allow to pricing wars • Should profitability of drugs be the same as other products? E.g. drugs vs airplanes? • Should govt change profitability? • Trade agreements • Public health imperatives vs tax breaks • Regulatory bodies and payers cannot react as quickly as the profitability

More Related